UA
50
-9
JWN
48
6
VMC
57
4
PFE
23
7
EOG
58
2
VRSN
53
-4
VFC
53
5
LNC
39
3
ORCL
65
-2
URI
65
5
CAH
48
-5
CSX
60
3
WEC
53
-2
USB
55
-6
PSA
58
2
RSG
71
3
SO
53
-4
PM
62
-2
TGT
22
2
BMY
60
2
UA
50
-9
JWN
48
6
VMC
57
4
PFE
23
7
EOG
58
2
VRSN
53
-4
VFC
53
5
LNC
39
3
ORCL
65
-2
URI
65
5
CAH
48
-5
CSX
60
3
WEC
53
-2
USB
55
-6
PSA
58
2
RSG
71
3
SO
53
-4
PM
62
-2
TGT
22
2
BMY
60
2
Financhill
Back

SpringWorks Therapeutics 10K Form

Buy
55

SWTX
SpringWorks Therapeutics

Last Price:
39.03
Seasonality Move:
51.03%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SWTX News And Ratings

See the #1 stock for the next 7 days that we like better than SWTX

SWTX Financial Statistics

Sales & Book Value

Annual Sales: $5.45M
Cash Flow: $-27.23M
Price / Cash Flow: 0
Annual Sales: $7.16
Price / Book: 5.45

Profitability

EPS (TTM): -3.89000
Net Income (TTM): $-275.16M
Gross Margin: $5.03M
Return on Equity: -51.38%
Return on Assets: -44.72%

SpringWorks Therapeutics Earnings Forecast

Key SpringWorks Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 3 years for SWTX is 92.25%.
  • The Selling, General & Administrative Expenses for SWTX have been equal to 3,626.79% of Gross Profit Margin.
  • The Research & Development expenses have been 2,762.75% of Revenue.
  • The Net Earning history of SWTX is -5,968.50% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

SpringWorks Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SWTX
CUSIP: 85205L
Website: springworkstx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.16
Quick Ratio: 5.8

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SWTX Technical Analysis vs Fundamental Analysis

Buy
55
SpringWorks Therapeutics (SWTX) is a Buy

Is SpringWorks Therapeutics a Buy or a Sell?